Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Coles AJ, Arnold DL, Bass AD, Boster AL, Compston DAS, Fernández Ó, Havrdová EK, Nakamura K, Traboulsee A, Ziemssen T, Jacobs A, Margolin DH, Huang X, Daizadeh N, Chirieac MC, Selmaj KW. Coles AJ, et al. Among authors: compston das. Ther Adv Neurol Disord. 2021 Apr 23;14:1756286420982134. doi: 10.1177/1756286420982134. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34035833 Free PMC article.
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fernández Ó, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS; CAMMS223, CAMMS03409, and TOPAZ Investigators. Steingo B, et al. Among authors: compston das. J Neurol. 2020 Nov;267(11):3343-3353. doi: 10.1007/s00415-020-09983-1. Epub 2020 Jun 24. J Neurol. 2020. PMID: 32583052 Free PMC article.
Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years.
Oh J, Achiron A, Celius EG, Chambers C, Derwenskus J, Devonshire V, Hellwig K, Hutton GJ, McCombe P, Moore M, Rog D, Schneider JR, Simm RF, Sousa L, Vincent SG, Chung L, Daizadeh N, Mitchell C, Compston DAS; CAMMS223, CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators. Oh J, et al. Among authors: compston das. Mult Scler Relat Disord. 2020 Aug;43:102146. doi: 10.1016/j.msard.2020.102146. Epub 2020 May 6. Mult Scler Relat Disord. 2020. PMID: 32498033 Free article. Clinical Trial.
Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study.
Wray S, Havrdova E, Snydman DR, Arnold DL, Cohen JA, Coles AJ, Hartung HP, Selmaj KW, Weiner HL, Daizadeh N, Margolin DH, Chirieac MC, Compston DAS. Wray S, et al. Among authors: compston das. Mult Scler. 2019 Oct;25(12):1605-1617. doi: 10.1177/1352458518796675. Epub 2018 Oct 5. Mult Scler. 2019. PMID: 30289355 Free PMC article. Clinical Trial.
Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis?
Cerqueira JJ, Compston DAS, Geraldes R, Rosa MM, Schmierer K, Thompson A, Tinelli M, Palace J. Cerqueira JJ, et al. Among authors: compston das. J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):844-850. doi: 10.1136/jnnp-2017-317509. Epub 2018 Apr 4. J Neurol Neurosurg Psychiatry. 2018. PMID: 29618493 Free PMC article. No abstract available.
Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL; CARE-MS II and CAMMS03409 Investigators. Coles AJ, et al. Among authors: compston das. Neurology. 2017 Sep 12;89(11):1117-1126. doi: 10.1212/WNL.0000000000004354. Epub 2017 Aug 23. Neurology. 2017. PMID: 28835403 Free PMC article.
171 results